000			02096 a2200553 4500
005			20250517173445.0
264		0	_c20180223
008			201802s 0 0 eng d
022			_a1537-6591
024	7		_a10.1093/cid/cix364 _2doi
040			_aNLM _beng _cNLM
100	1		_aButt, Adeel Ajwad
245	0	0	_aEffect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. _h[electronic resource]
260			_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _cSep 2017
300			_a1006-1011 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_a2-Naphthylamine
650	0	4	_aAged
650	0	4	_aAnilides _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aBenzimidazoles _xtherapeutic use
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aCyclopropanes
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aFluorenes _xtherapeutic use
650	0	4	_aHepatitis C, Chronic _xdrug therapy
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLactams, Macrocyclic
650	0	4	_aMacrocyclic Compounds _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProline _xanalogs & derivatives
650	0	4	_aPropensity Score
650	0	4	_aProportional Hazards Models
650	0	4	_aRitonavir _xtherapeutic use
650	0	4	_aSofosbuvir _xtherapeutic use
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aSurvival Rate
650	0	4	_aSustained Virologic Response
650	0	4	_aUracil _xanalogs & derivatives
650	0	4	_aValine
700	1		_aYan, Peng
700	1		_aSimon, Tracey G
700	1		_aAbou-Samra, Abdul-Badi
773	0		_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 65 _gno. 6 _gp. 1006-1011
856	4	0	_uhttps://doi.org/10.1093/cid/cix364 _zAvailable from publisher's website
999			_c27558347 _d27558347